CZ20031909A3 - Tlumené protilátky proti CD 28 a jejich použití - Google Patents

Tlumené protilátky proti CD 28 a jejich použití

Info

Publication number
CZ20031909A3
CZ20031909A3 CZ20031909A CZ20031909A CZ20031909A3 CZ 20031909 A3 CZ20031909 A3 CZ 20031909A3 CZ 20031909 A CZ20031909 A CZ 20031909A CZ 20031909 A CZ20031909 A CZ 20031909A CZ 20031909 A3 CZ20031909 A3 CZ 20031909A3
Authority
CZ
Czechia
Prior art keywords
attenuated
antibodies against
antibodies
attenuated antibodies
Prior art date
Application number
CZ20031909A
Other languages
English (en)
Inventor
J. Yun Tso
Paul Hinton
Maximiliano Vasquez
Kouichi Tamura
Yasuyuki Higashi
Nobuo Seki
Hirotsugu Ueda
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of CZ20031909A3 publication Critical patent/CZ20031909A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CZ20031909A 2000-12-14 2001-12-14 Tlumené protilátky proti CD 28 a jejich použití CZ20031909A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14

Publications (1)

Publication Number Publication Date
CZ20031909A3 true CZ20031909A3 (cs) 2003-11-12

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20031909A CZ20031909A3 (cs) 2000-12-14 2001-12-14 Tlumené protilátky proti CD 28 a jejich použití

Country Status (18)

Country Link
EP (1) EP1341553A4 (cs)
JP (1) JP2004515243A (cs)
KR (1) KR20040020866A (cs)
CN (1) CN1272345C (cs)
AR (1) AR031924A1 (cs)
AU (2) AU2002226086C1 (cs)
BR (1) BR0116686A (cs)
CA (1) CA2432736A1 (cs)
CZ (1) CZ20031909A3 (cs)
HU (1) HUP0400697A3 (cs)
IL (1) IL156262A0 (cs)
MX (1) MXPA03005327A (cs)
NO (1) NO20032542L (cs)
NZ (1) NZ526569A (cs)
PL (1) PL363239A1 (cs)
RU (1) RU2261723C2 (cs)
WO (1) WO2002047721A1 (cs)
ZA (1) ZA200305384B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
FR2951176A1 (fr) 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
CA2788544C (en) * 2010-02-18 2019-03-05 Effimune Anti-cd28 humanized antibodies
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020183471A1 (en) * 2019-03-14 2020-09-17 Biond Biologics Ltd. A method for immunosuppression
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein

Also Published As

Publication number Publication date
CN1272345C (zh) 2006-08-30
AU2608602A (en) 2002-06-24
AU2002226086C1 (en) 2006-03-09
BR0116686A (pt) 2003-12-30
RU2261723C2 (ru) 2005-10-10
EP1341553A1 (en) 2003-09-10
IL156262A0 (en) 2004-01-04
AU2002226086B2 (en) 2005-08-25
EP1341553A4 (en) 2004-07-28
RU2003121231A (ru) 2005-02-10
AR031924A1 (es) 2003-10-08
ZA200305384B (en) 2004-10-11
WO2002047721A1 (en) 2002-06-20
HUP0400697A2 (hu) 2004-06-28
MXPA03005327A (es) 2004-12-03
NO20032542L (no) 2003-08-07
KR20040020866A (ko) 2004-03-09
JP2004515243A (ja) 2004-05-27
PL363239A1 (en) 2004-11-15
CA2432736A1 (en) 2002-06-20
HUP0400697A3 (en) 2007-05-02
CN1489473A (zh) 2004-04-14
NO20032542D0 (no) 2003-06-05
NZ526569A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
IL151853A (en) Multivalent antibodies and uses thereof
IL154325A (en) Isolated anti-il-12 antibody and composition comprising the same
GB0029360D0 (en) Humanised antibodies and uses thereof
EP1274424A4 (en) CONNECTIONS AND PROCEDURE
CZ20031909A3 (cs) Tlumené protilátky proti CD 28 a jejich použití
GB9927332D0 (en) Novel antibody and uses thereof
IL156161A0 (en) Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
AU2001240637A1 (en) Novel imidazotriazinones and the use thereof
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
EP1302770A4 (en) PARTICLE MARKING PROTEIN AND IMMUNO-CHROMATOGRAPHER USING THE SAME
GB0028879D0 (en) Adsorbents and their use
GB0021497D0 (en) Compounds and their use
GB0007530D0 (en) Trityl-type compounds and their use
AU2001260133A1 (en) Alkoxylated perfumed alcohols and the use thereof
AU2001261534A1 (en) The meca-79 antigen and related methods
EP1343796A4 (en) COMPOUNDS AND METHODS
AU2002256556A1 (en) Sea-trosy and related methods
HU0103040D0 (en) High - level source and it's application
HK1047943A1 (zh) 黏膜炎莫拉氏菌basb114抗原及其用途
PL359171A1 (en) Composition and use
EP1437367A4 (en) ANTIBODIES AND ITS USE
AU2001263934A1 (en) Inlet device and its use
GB0008876D0 (en) IC2CU and IC2IDU
GB0018146D0 (en) Complexes and their use